We suggest that the important predictors in determining outcome post-LT for HCC patients with HBV-associated cirrhosis are not just the pathologic tumor factors, but also the AFP levels, liver function levels and pre-LT antitumor therapy. The gene discussed is AFP; the disease is Cirrhosis.